

**DIASORIN LAUNCHES THE FIRST FULLY AUTOMATED CLIA TEST AVAILABLE IN THE WORLD FOR THE DETERMINATION OF THE 1,25 VITAMIN D ON ITS LIAISON XL**

June 03, 2014 - Saluggia (VC) - **DiaSorin** (FTSE Mid Cap:DIA) is proud to announce the **launch of its novel 1,25 Dihydroxyvitamin D assay** for the quantitative determination of 1,25 Dihydroxyvitamin D levels in human serum and plasma, **available on the LIAISON XL** analyzer for the market outside the US only.

The new DiaSorin **1,25 Vitamin D** is the **only fully automated product available in the world on the CLIA technology** and represents a further milestone of the Group in the bone and mineral clinical area.

**The 1,25 Dihydroxyvitamin D** is the biological active form of Vitamin D and it is a **test run by the same laboratories already performing the Vitamin D 25 OH test** where DiaSorin is the undisputed leader in the world.

Mr. Chen Even, Senior Corporate VP Commercial Operations of the DiaSorin Group, commented: *"The 1,25 Dihydroxyvitamin D testing volume is between 10% and 15% of the current Vitamin D market, which is above 115 million of Euro in Europe and it's growing double digit. We want to consistently address this market leveraging on our strong positioning on the Vitamin D franchise thanks to the quality of our products and the continuous success of our LIAISON XL. By year end we also expect to receive the approval for the test in the US market"*.

Low levels of Vitamin D can be correlated with various clinical conditions, such as chronic kidney disease, rickets type 1, and hypoparathyroidism, while high levels can be found in rickets type 2, sarcoidosis, rheumatoid arthritis, IBD, and primary hyperparathyroidism.

**The DiaSorin LIAISON XL assay is the first fully automated 1,25 Dihydroxyvitamin D assay available today.** Until now 1,25 Dihydroxyvitamin D assays have required a challenging manual, time consuming, operator dependent up-front extraction step in order to isolate the 1,25 Dihydroxyvitamin D.

**The novel LIAISON XL method** does not require the sample pre-treatment, offering higher efficiency and quality of the **results in just 65 minutes**.

With its analytical excellence, **the novel assay will enhance DiaSorin's unique LIAISON Bone and Mineral menu**, which today includes 25 OH Vitamin D TOTAL Assay, N-TACT PTH Gen II, 1-84 PTH, BAP OSTASE and Osteocalcin, providing convenience and accuracy of results.

Carlo Rosa, CEO of DiaSorin Group, commented: *"Our new 1,25 Vitamin D on the LIAISON XL is a true game changer in laboratory efficiency. This new product represents our capability in being always innovative and developing products that our clients really need."*

*We believe the new 1,25 Vitamin D is a breakthrough and we consider it as the first test of a new set of products that the Group is developing for the future, leveraging on the same raw materials of the test launched today”.*

**REFERENCE TABLE FOR DIASORIN PRODUCTS**

<b>Assay name</b>	1,25 Dihydroxyvitamin D		
<b>Diagnosis</b>	Quantitative determination of 1,25 Dihydroxyvitamin D levels in human serum and plasma		
<b>Potential market</b>	Between 10% and 15% of the current Vitamin D market, which is above € 115 mln in Europe		
<b>Business segment</b>	Immunodiagnosics	✓	Molecular Diagnostics
<b>Technology</b>	CLIA	✓	Extraction
	ELISA		Amplification/Detection
	RIA		HLA Typing
<b>Clinical Area</b>	Infectious Disease		Infectious Disease
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		
	Bone & Mineral	✓	Onco-hematology
	Cardiac Markers		
	GI Stool Testing		

**About DiaSorin**

*DiaSorin is an Italian multinational Group, worldwide leader in the field of In Vitro Diagnostics (IVD), and it is listed in the FTSE Italy Mid Cap Index. For over 40 years, the Group has been developing, manufacturing and selling worldwide tests (blood test kits) for diagnosis of diseases in various clinical areas. DiaSorin’s offer is aimed at laboratories and hospitals and is able to satisfy every type of requirement related to infectious diseases, cardiac markers, bone and metabolism, hepatitis and retrovirus, oncology and endocrinology. DiaSorin offers to the market such a unique menu of immunodiagnostic tests in terms of width and specialty that it has earned the definition of “In Vitro Diagnostic Specialist”. Within the IVD market, DiaSorin is also focusing on offering products for molecular diagnostics.*

**For additional information, please contact:**

**Riccardo Fava**

External Relations Director - Head of IR and Media

Tel: +39.0161.487988

[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

**Margherita Sacerdoti**

Investor Relations Specialist

Tel: +39.0161.487456

[margherita.sacerdoti@diasorin.it](mailto:margherita.sacerdoti@diasorin.it)